Although changes in T-cell proliferation and survival in the timepoint analyzed may have contributed to the increase in T-cell infiltration, the effects of CTLA-4 and PD-L1 antibodies treatment on tumor growth and T-cell function was still evident i.e., tumors undergoing both monotherapy and combined therapy were approximately half the volume of the controls and the number of GFP+ T-cells was 3–5-fold higher in both the peritumoral and intratumoral regions of the ICI-treated mice compared to the controls. Here, CTLA4 is linked to neoplasm.